综合疗法治疗带状疱疹56例疹疗效观察

目的观察泛昔洛韦联合白介素肌肉注射配合紫外线光疗治疗带状疱疹的疗效。方法选择在本院皮肤科就诊的明确诊断为带状疱疹病患者98例,随机分为两组,分别予单独泛昔洛韦口服（对照组）和应用泛昔洛韦口服白介素肌肉注射,紫外线光疗仪联合治疗（治疗组）。结果治疗组联合治疗7d56例病人痊愈率（94．6％）高于对照组（73．8％）,差异有统计学意义（P〈0．01）。且治疗组在止痛时间、止疱时间、结痂时间三方面均明显优于对照组（P〈0．05）。结论泛昔洛韦加白介素联合紫外线光疗仪治疗带状疱疹能缩短疗程,不留后遗症,效果甚佳。     

Chronische Schmerzen bei Herpes Zoster

Zum Thema Der Zostererkrankung liegt eine Entzündung des Spinalganglions bzw. der Ganglien entsprechend befallener Hirnnerven zugrunde. Ursache ist die Reaktivierung einer latenten Infektion mit dem neurotropen Varizella-Herpes-Zoster Virus. Wesentlicher Risikofaktor dafür ist neben dem Lebensalter eine Abwehrschw?che, wie sie oft bei Malignomen und deren einschneidenden Therapien sowie bei immunkompromittierenden Erkrankungen, z.B. HIV-Infektionen, angetroffen wird. Jeder Herpes Zoster sollte, ohne da? andere Erkrankungen bekannt w?ren, im Umkehrschlu? den behandelnden Arzt veranlassen, an ein Malignom zu denken und danach zu fahnden! Der stechende Zosterschmerz der Akutphase wird exakt im befallenen Dermatom lokalisiert, der postzosterische und von den Betroffenen als qu?lend empfundene brennende Dauerschmerz strahlt auch in die Nachbarsegmente aus. Es kann eine überempfindlichkeit auch auf leichteste Berührungsreize herrschen, oft unterbrochen von attackenweise stechenden Schmerzen. Die Inzidenz und die Persistenz postzosterischer Schmerzen nimmt mit dem Lebensalter deutlich zu. Wenn auch nicht immer ganz erfolgreich, so werden die chronischen Schmerzen doch meistens durch eine ausgeklügelte Therapie wesentlich gebessert, eventuell nach vorherigen pr?ventiven Ma?nahmen in der Akutphase.     

TDP加低功率氦—氖激光治疗带状疱疹42例疗效观察

本文对８２例带状疱疹患者随机分为ＴＤＰ加氦－氦激光组和药物组，经１个疗程治疗结果表明：ＴＤＰ加氦－氖激光组的疗效明显优于药物组，ＴＤＰ加氦－氖激光治疗带状疱疹的效果显著、疗程短、无痛苦、无毒副作用。     

A case of herpes zoster with abducens palsy

Only a few reports have focused on ocular motor paralysis in herpes zoster ophthalmicus. We report a case of ocular motor paralysis resulting from herpes zoster. The patient, an 80-yr-old woman, presented with grouped vesicles, papules, and crusting in the left temporal area and scalp, with diplopia, impaired gaze, and severe pain. Her cerebrospinal fluid analysis was positive for varicellar zoster virus IgM. Magnetic resonance imaging was performed to rule out other diseases causing diplopia; there were no specific findings other than old infarctions in the pons and basal ganglia. Therefore, she was diagnosed of abducens nerve palsy caused by herpes zoster ophthalmicus. After 5 days of systemic antiviral therapy, the skin lesions improved markedly, and the paralysis was cleared 7 weeks later without extra treatment.     

Generalisierte Follikulär-Pustulöse Candidose nach Herpes Zoster*: Generalized Pustular Candidosis Following Herpes Zoster Infection

Zusammenfassung: Es wird über eine offensichtlich seltene kntane Kandidose berichtet, welche in diesem Fall im Anschlnß an eine Herpes-zoster-Infektion aufgetreten ist. Diese Candida-Dermatitis, die man als ?generalisierte follikulär-pustulöse Dermatitis candidosa” bezeichnen könnte, manifestlerte sich ?exanthematiseh” an Stamm und Unterarmen. In den Pusteln konnte Candida albicans nachgewiesen werden. Unter entsprechender Lokal und Allgemeintherapie Kam es znr Abheilung. Eine ?relative Immundefizienz” wird als pathogenetisch maßgeblich erachtet. Summary: We report an uncommon aise of cutaneons candidosis. Following a herpes zoster eruption a pustular rash involving the trunk and the lower arms developed. Candida albicans was found within the pustules. Tbe eruption cleared on topical and systemic measures. We propose the term “generalized follicular pustular cutaneons candidosis” and consider a relative immune deficiency as a causative factor.     

Cell mediated immunity to meet the avian influenza A (H5N1) challenge

Avian influenza A subtype H5N1 virus with its recombination potential with the human influenza viruses presents a threat of producing a pandemic. The consensus is that the occurrence of such a pandemic is only a matter of time. This is of great concern, since no effective vaccine is available or can be made before the occurrence of the event. We present arguments for the use of cell mediated immunity for the prevention of the infection as well as for the treatment of infected patients. Transfer factor (TF), an immunomodulator of low molecular weight capable of transferring antigen-specific cell mediated immune information to T-lymphocytes, has been used successfully over the past quarter of a century for treating viral, parasitic, and fungal infections, as well as immunodeficiencies, neoplasias, allergies and autoimmune diseases. Moreover, several observations suggest that it can be utilised for prevention, transferring immunity prior to infection. Because it is derived from lymphocytes of immune donors, it has the potential to answer the challenge of unknown or ill-defined pathogens. Indeed, it is possible to obtain an antigen-specific TF preparation to a new pathogen before its identification. Thus, a specific TF to a new influenza virus can be made swiftly and used for prevention as well as for the treatment of infected patients.     

Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England

This study updates previous work on modelling the incidence of varicella and Herpes Zoster (HZ) following the introduction of childhood vaccination. The updated model includes new data on age-specific contact patterns, as well as data on the efficacy of zoster vaccination in the elderly and allows for HZ among vaccinees. The current study also looks at two-dose varicella childhood programmes, and assesses the combined impact of varicella vaccination in childhood and zoster vaccination of the elderly. The results suggest that a two-dose schedule is likely to reduce the incidence of varicella to very low levels, provided first dose coverage is around 90% and second dose coverage is in excess of 70%. Single dose varicella vaccination programmes are expected to result in large numbers of breakthrough cases. Childhood vaccination is expected to increase the incidence of zoster for more than 40 years after introduction of the programme, the magnitude of this increase being influenced primarily by the duration of boosting following exposure to the varicella zoster virus. Though this increase in zoster incidence can be partly offset by vaccination of the elderly, the effectiveness of this combined strategy is limited, as much of the increase occurs in those adults too young to be vaccinated. Childhood vaccination at intermediate levels of coverage (70% and 60% for first and second dose coverage respectively) is expected to lead to an increase in adult varicella. At high coverage (90% and 80% coverage) this is unlikely to be the case. These results will be used to inform a cost-effectiveness analysis of combined varicella and zoster vaccination programmes.